Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data.

Akyüz, Filiz; Çavuş, Bilger; Nizam, Nihan; Göktürk, Suut; Baran, Bülent; Yazıcı, Halil; Evirgen, Sami; Akyüz, Ümit; Öbekli, Tuba; Karaca, Çetin; Demir, Kadir; Beşışık, Fatih; Kaymakoğlu, Sabahattin

doi:10.5114/ceh.2022.114153

Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data.

Atıf İçin Kopyala

Akyüz F., Çavuş B., Nizam N., Göktürk S., Baran B., Yazıcı H., ...Daha Fazla

Clinical and experimental hepatology, cilt.8, sa.1, ss.7-13, 2022 (Hakemli Dergi)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 8 Sayı: 1
Basım Tarihi: 2022
Doi Numarası: 10.5114/ceh.2022.114153
Dergi Adı: Clinical and experimental hepatology
Sayfa Sayıları: ss.7-13
Anahtar Kelimeler: safety, tenofovir, renal transplantation, hemodialysis, chronic hepatitis B, FUMARATE, ALAFENAMIDE, PHARMACOKINETICS, DYSFUNCTION, THERAPY
İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: There are limited data about the safety of tenofovir disoproxil fumarate (TDF) in chronic renal failure (CRF). In this study, we aimed to evaluate the safety and efficacy of TDF in renal transplant recipients and hemodialysis patients with chronic hepatitis B (CHB) during long-term follow-up.